Government Initiatives in Promoting Cell & Gene Therapy Manufacturing & its Associated Supply Chain in the UK

In by

Spotlight Article

INTERVIEW

Magdalani Papadaki

SUPPLY CHAIN MANAGEMENT PART 2: CREATING A LOGISTICS STRATEGY FOR COMMERCIALIZATION

Dr Magdalini Papadaki is Head of Product and Process Innovation for ABPI. She is responsible for the UK’s industry strategy in innovative products (i.e. ATMPs, Synthetic Biology, new R&D tools) and novel development pathways for accelerated production and regulatory/clinical assessment. Before joining ABPI, Magda was a Lead Technologist for the Innovate UK Regenerative Medicine program. She is also a subject matter expert on adaptive pathways and new iterative development approaches and was member of the NEWDIGS consortium on the Adaptive Licensing paradigm in MIT, Boston, MA. A stem cell and gene therapy scientist by training, combining over a decade in research with regulatory and business experience in the EU and USA. Magda has worked extensively in the global space of public–private partnerships, including the EU Innovative Medicines Initiative (IMI) and the US/FDA Critical Path initiative. Her industry experience was with Novartis, as OTC DRA and Access Director for Greece and Cyprus. She holds a PhD in Gene Therapy and Stem Cells, an MPhil in Bioscience Enterprise from the University of Cambridge, UK and an MSc in Pharmacology from the University of Oxford, UK.

DOI: 10.18609/cgti.2018.041
Citation: Cell Gene Therapy Insights 2018;4(5), 397-404.
Open access

This content is restricted to registered users. Click here to Register or Login here.